No new concerns with Moderna’s coronavirus vaccine: US FDA

U.S. Food and Drug Administration staff members did not raise new concerns over data on Moderna Inc’s coronavirus vaccine in documents made public on Tuesday, preparing the way for U.S. authorization of a second, easier-to-handle vaccine.

The FDA staff said a two-dose regimen of Moderna’s vaccine was highly effective in preventing confirmed cases of COVID-19. The comments were made in documents prepared for Thursday’s meeting of outside experts, who will discuss whether to endorse a U.S. emergency use authorization (EUA) for the Moderna vaccine.

The FDA reviewers did not raise any specific safety issues with using the vaccine in adults over the age of 18.

They said that serious side effects in the trial of the vaccine represented medical events that occur in the general population at a similar frequency as observed in the study.

The United States has planned to deliver 40 million vaccine doses – enough for 20 million people – this month, which includes both the vaccine from Moderna and the one developed by Pfizer Inc and BioNTech SE, which was granted an (EUA) by the FDA late on Friday.

You have reached your limit for free articles this month.

Subscription Benefits Include

Today’s Paper

Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.

Unlimited Access

Enjoy reading as many articles as you wish without any limitations.

Personalised recommendations

A select list of articles that match your interests and tastes.

Faster pages

Move smoothly between articles as our pages load instantly.

Dashboard

A one-stop-shop for seeing the latest updates, and managing your preferences.

Briefing

We brief you on the latest and most important developments, three times a day.

Support Quality Journalism.

*Our Digital Subscription plans do not currently include the e-paper, crossword and print.

Thank You

Leave a Reply